Montana § 37-7-502 Definitions

Montana Statutes

§ 37-7-502 — Definitions

Montana § 37-7-502

Title 37PROFESSIONS AND OCCUPATIONS

Ch. 7PHARMACY

Part 5Drug Product Selection

This text of Montana § 37-7-502 (Definitions) is published on Counsel Stack Legal Research, covering Montana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Mont. Code Ann. § 37-7-502 (2026).

Text

37-7-502 . Definitions. As used in this part, the following definitions apply:

(1)"Bioavailability" means the extent and rate of absorption from a dosage form as reflected by the time-concentration curve of the administered drug in the systemic circulation.

(2)"Bioequivalent" means a chemical equivalent that, when administered to the same individual in the same dosage regimen, will result in comparable bioavailability.

(3)"Biological product" has the meaning provided in 42 U.S.C. 262.

(4)"Brand name" means the proprietary or the registered trademark name given to a drug product by its manufacturer, labeler, or distributor and placed upon the drug, its container, label, or wrapping at the time of packaging.

(5)"Chemical equivalent" means drug products that contain the same amounts of t

Free access — add to your briefcase to read the full text and ask questions with AI

37-7-502 . Definitions. As used in this part, the following definitions apply:
(1) "Bioavailability" means the extent and rate of absorption from a dosage form as reflected by the time-concentration curve of the administered drug in the systemic circulation.
(2) "Bioequivalent" means a chemical equivalent that, when administered to the same individual in the same dosage regimen, will result in comparable bioavailability.
(3) "Biological product" has the meaning provided in 42 U.S.C. 262.
(4) "Brand name" means the proprietary or the registered trademark name given to a drug product by its manufacturer, labeler, or distributor and placed upon the drug, its container, label, or wrapping at the time of packaging.
(5) "Chemical equivalent" means drug products that contain the same amounts of the same therapeutically active ingredients in the same dosage forms and that meet present compendium standards.
(6) "Drug product" means a dosage form containing one or more active therapeutic ingredients along with other substances included during the manufacturing process.
(7) "Generic name" means the chemical or established name of a drug product or drug ingredient published in the latest edition of an official compendium recognized by the board.
(8) "Interchangeable biological product" means a biological product that the federal food and drug administration has:
(a) licensed; and
(b) (i) determined meets the standards for interchangeability pursuant to 42 U.S.C. 262(k)(4); or
(ii) determined is therapeutically equivalent as set forth in the latest edition of or supplement to the federal food and drug administration's approved drug products with therapeutic equivalence evaluations.
(9) "Person" has the meaning provided in 37-7-101 .
(10) "Prescriber" means a medical practitioner, as defined in 37-2-101 , licensed under the professional laws of the state to purchase, administer, and prescribe medicine and drugs. For the purposes of this chapter, the term includes a naturopathic physician and a physician assistant.
(11) "Present compendium standard" means the official standard for drug excipients and drug products listed in the latest revision of an official compendium recognized by the board.
(12) "Product selection" means to dispense without the prescriber's express authorization a different drug product in place of the drug product prescribed.
(13) "Therapeutically equivalent" means those chemical equivalents that, when administered in the same dosage regimen, will provide essentially the same therapeutic effect as measured by the control of a symptom or a disease and/or toxicity.

Legislative History

En. 66-1529 by Sec. 2, Ch. 403, L. 1977; R.C.M. 1947, 66-1529; amd. Sec. 11, Ch. 379, L. 1981; amd. Sec. 12, Ch. 388, L. 2001; amd. Sec. 1, Ch. 42, L. 2017; amd. Sec. 7, Ch. 726, L. 2025.